CA Patent

CA3138560A1 — Imidazopyrimidines as eed inhibitors and the use thereof

Assigned to University of Michigan System · Expires 2021-01-21 · 5y expired

What this patent protects

The present disclosure provides compounds represented by Formula (I) wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are as defined in the specification, and the salts and solvates thereof. Compounds of Formul…

USPTO Abstract

The present disclosure provides compounds represented by Formula (I) wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are as defined in the specification, and the salts and solvates thereof. Compounds of Formula (I) are FED inhibitors. FED inhibitors are useful for the treatment of cancer and other diseases.

Drugs covered by this patent

Patent Metadata

Patent number
CA3138560A1
Jurisdiction
CA
Classification
—
Expires
2021-01-21
Drug substance claim
No
Drug product claim
No
Assignee
University of Michigan System
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.